ArticleEsophagus : official journal of the Japan Esophageal Society2026
Serum microRNAs for the assessment of symptomatically refractory gastroesophageal reflux disease despite acid suppression.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcid suppression with proton pump inhibitors (PPIs) or a potassium-competitive acid blocker (P-CAB) is the first-line treatment for gastroesophageal reflux disease (GERD); however, a significant proportion of patients exhibit symptomatically refractory GERD. Here, we investigated whether distinct serum miRNA profiles exist in individuals with persistent symptoms despite acid suppression, given that serum miRNAs are promising biomarkers for cancer detection and various pathophysiological conditions. We also examined the relationship between anxiety/depression and serum miRNAs associated with symptomatic refractoriness.
methodsGERD patients taking PPIs/P-CAB for at least 8 weeks were enrolled and were classified into symptomatically refractory and symptomatically responsive groups using a GerdQ questionnaire. Comprehensive serum miRNA profiling was performed for all participants. Logistic LASSO/Elastic Net regression analysis was used to identify miRNAs associated with symptomatic refractoriness to PPIs/P-CAB, and a discriminant model was developed. Associations of the identified miRNAs with the presence of reflux esophagitis (RE) and items on the Hospital Anxiety and Depression Scale (HADS) were assessed.
resultsA combination of four serum miRNAs (miR-4294, miR-4725-3p, miR-3679-5p, and miR-6893-5p) was able to distinguish the symptomatically refractory group from the responsive group (sensitivity, 0.83; specificity, 0.66; AUC, 0.79). This AUC was higher than that for the presence of RE. The serum levels of three of the four miRNAs were associated with items on the HADS-A subscales.
conclusionsDistinct serum miRNA profiles are associated with symptom persistence despite acid suppression, potentially reflecting neuropsychological factors. These findings may provide new insights into the complex pathophysiology of symptomatically refractory GERD.
Indexed as
Identifiers
42474877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.